ORGS Overview

Earnings Release: ORGENESIS is set to announce its quarterly earnings on April 14th, with analysts predicting revenue of $24.68 million and earnings of $0.26 per share.

Investor Activity: There has been no increase in institutional investment in ORGENESIS stock recently, with one institution decreasing its position in the last quarter.

Orgenesis Stock Update: Orgenesis Inc. has transitioned to trading on the OTCQX Best Market after being delisted from Nasdaq due to not meeting stockholders' equity requirements, and plans to reapply for a Nasdaq listing once the deficiency is resolved.

Decentralized Cell Processing Platform: The company is advancing its Decentralized Cell Processing platform aimed at making cell and gene therapies more accessible and affordable through partnerships with hospitals and research institutions globally.

U.S. Stock Market Performance: U.S. stocks showed mixed results, with the Dow Jones falling over 100 points while the NASDAQ and S&P 500 gained. Notable movements included Netflix reporting strong third-quarter results and significant increases in shares for Catheter Precision and Bright Minds Biosciences.

Global Market Trends: European shares were mixed, with declines in construction output, while Asian markets closed higher. In commodities, oil prices fell, but gold and silver saw gains. U.S. housing starts and building permits also experienced declines in September.

Intuitive Surgical Performance: Intuitive Surgical, Inc. shares rose 6.9% in pre-market trading after reporting better-than-expected third-quarter financial results and receiving regulatory clearance for the da Vinci 5 surgical system in South Korea.

Market Movements: Several stocks experienced significant changes in pre-market trading, with notable gainers including SOBR Safe, Inc. (+95.2%) and Netflix, Inc. (+5.8%), while losers included Orgenesis Inc. (-48.3%) and NuZee, Inc. (-38.7%).

Maison Solutions Inc. Performance: Shares of Maison Solutions Inc. surged 91.4% in pre-market trading after reporting a 114.49% year-over-year increase in first-quarter sales, reaching $29.60 million.

Market Movements: Other notable pre-market stock movements included Heart Test Laboratories gaining 69.7%, while BioVie Inc. fell 52.4% following a secondary stock offering.

Stock Performance and Reverse Split: Orgenesis Inc (ORGS) shares fell 21% to 40 cents after announcing a 1-for-10 reverse stock split, effective September 24, to meet Nasdaq's $1.00 minimum bid price requirement, reducing outstanding shares from 47.7 million to approximately 4.77 million.

Investment Considerations: The stock has decreased by 29.34% over the past year and 37.67% in the last month, with an all-time high of $5.02 indicating significant potential upside from current levels, but investors should evaluate their time horizon and unrealized gains before making decisions.